GHENT, Belgium--(BUSINESS WIRE)--June 1, 2006--Ablynx, the pioneer in the discovery and development of Nanobodies(TM), a novel class of antibody-derived therapeutic proteins, has announced the appointment of Eva-Lotta Allan as Chief Business Officer (CBO). Eva-Lotta brings more than 12 years experience in business development, and joins Ablynx from Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX - News) where she was Senior Director of Business Development and Site Operations (Vertex Europe). In this role she was instrumental in leading cross-functional deal teams, identifying, structuring, negotiating and closing deals, and key contributor to the Vertex business strategies. She recently negotiated and finalized a product licensing agreement with GlaxoSmithKline for one of Vertex’s development candidates for a total value greater than USD400 Million excluding royalties. Prior to joining Vertex she held senior business development and marketing roles during ten years at Oxford Asymmetry International plc and Oxford GlycoSciences plc.
